Overview

Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)

Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate the bioequivalence between the formulation of 5 mg/mL Tramadol Hydrochloride Oral Solution (08P1902F0) Relative to the reference product Contramal® (100 mg/mL Oral Solution).
Phase:
Phase 1
Details
Lead Sponsor:
Unither Pharmaceuticals, France
Collaborator:
International Pharmaceutical Research Center
Treatments:
Pharmaceutical Solutions
Tramadol